A Study of ULTRAM ER at Two Dose Levels in Adolescents With Pain

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier:
NCT01586507
First received: April 25, 2012
Last updated: August 28, 2012
Last verified: August 2012

April 25, 2012
August 28, 2012
October 2007
September 2008   (final data collection date for primary outcome measure)
The area under the curve (AUC∞) of ULTRAM ER as the primary PK parameter [ Time Frame: At 1, 4, 6, 8, 12, 16, 24, 36, and 48 hours post dose ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01586507 on ClinicalTrials.gov Archive Site
  • Plasma concentration profile of ULTRAM ER [ Time Frame: At 1, 4, 6, 8, 12, 16, 24, 36, and 48 hours post dose ] [ Designated as safety issue: No ]
  • Plasma concentration profiles of M1 and M5 metabolites [ Time Frame: At 1, 4, 6, 8, 12, 16, 24, 36, and 48 hours post dose ] [ Designated as safety issue: No ]
  • Incidence of adverse events as a measure of safety and tolerability [ Time Frame: 48 hours post dose ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study of ULTRAM ER at Two Dose Levels in Adolescents With Pain
A Single Dose Pharmacokinetic, Tolerability, and Safety Study of ULTRAM ER at Two Dose Levels in Adolescents Twelve to Seventeen Years Old, Inclusive, With Pain

The purpose of this study is to compare the pharmacokinetic (PK) of single oral doses of ULTRAM Extended Release (ER) at 2 dose levels in adolescents between 12 and 17 years old, inclusive (up to 17 years 364 days) with pain due to injury or nonmalignant disease, to the PK in adults, with respect to the PK parameter AUC∞ (area under the curve) of racemic tramadol. PK explores how the drug is absorbed in the body, distributed within the body, and how it is removed from the body over time.

This is a multicenter, open-label (all people know the identity of the intervention), 2-group, single dose study. Within each group of participants for Parts 1 and 2, at least 1/3 of the participants will be female, at least 1/3 of the participants will be male, at least 1/3 of the participants will be below the age of 14 years, and at least 1/3 of the participants will be above the age of 16 years. Participants will be assigned to 1 group only. Each group of participants will receive a single oral dose of ULTRAM ER on 1 occasion. Group 1 will receive a dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments. Following completion of all evaluations of Group 1, the pharmacokinetic data will be evaluated to target a dose for Group 2 that will achieve a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults. The maximum dose of ULTRAM ER should not exceed 6 mg/kg or 300 mg. When the study physician, the investigators, and the medical monitors agree that the PK of the drug is well-characterized and that the drug is well tolerated, enrollment will begin for Group 2 of the study. The sponsor's responsible Medical Officer will evaluate the safety of the calculated dose in Group 2 participants by evaluation of adverse drug events paying particular attention to events suggestive of either opioid toxicity or serotonin toxicity.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Pain
  • Drug: ULTRAM ER
    One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
  • Drug: ULTRAM ER
    The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
  • Experimental: Group 1
    Intervention: Drug: ULTRAM ER
  • Experimental: Group 2
    Intervention: Drug: ULTRAM ER
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
38
September 2008
September 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Confirmed need for control of pain due to injury or nonmalignant disease that does not influence fluid shifts and general drug disposition
  • Weighs at least 30 kg
  • Female participants must be premenarchal, surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control
  • Able to swallow the intact tablet with the aid of water (participants may not chew, divide, dissolve, or crush the study drug)
  • Signed informed consent document indicating that he/she understands the purpose of and procedures required for the study and is willing to participate in the study
  • Informed consent signed by the parent(s) or the legal guardian(s) of the participant

Exclusion Criteria:

  • History of or current clinically significant medical illness or condition including (but not limited to) cardiac disease, hematologic disease, coagulation disorders, lipid abnormalities, significant pulmonary disease, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, neurologic or psychiatric disease, infection, or any other illness or condition that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results
Both
12 Years to 17 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01586507
CR014017, TRAMAPPAI1003
No
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Not Provided
Study Director: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Clinical Trial Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP